Phaseline

Companies › Exegenesis Bio

Exegenesis Bio: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EXG102-031
Blocks abnormal blood vessel formation and leakage
–Phase 1Neovascular Age-Related Macular Degeneration (nAMD)Feb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06817343EXG102-031Phase 1Neovascular Age-Related Macular Degeneration (nAMD)OphthalmologyFeb 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.